Literature DB >> 16579622

Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies.

Dirk Chelius1, Kay Jing, Alexis Lueras, Douglas S Rehder, Thomas M Dillon, Alona Vizel, Rahul S Rajan, Tiansheng Li, Michael J Treuheit, Pavel V Bondarenko.   

Abstract

The status of the N-terminus of proteins is important for amino acid sequencing by Edman degradation, protein identification by shotgun and top-down techniques, and to uncover biological functions, which may be associated with modifications. In this study, we investigated the pyroglutamic acid formation from N-terminal glutamic acid residues in recombinant monoclonal antibodies. Almost half the antibodies reported in the literature contain a glutamic acid residue at the N-terminus of the light or the heavy chain. Our reversed-phase high-performance liquid chromatography-mass spectrometry method could separate the pyroglutamic acid-containing light chains from the native light chains of reduced and alkylated recombinant monoclonal antibodies. Tryptic peptide mapping and tandem mass spectrometry of the reduced and alkylated proteins was used for the identification of the pyroglutamic acid. We identified the formation of pyroglutamic acid from N-terminal glutamic acid in the heavy chains and light chains of several antibodies, indicating that this nonenzymatic reaction does occur very commonly and can be detected after a few weeks of incubation at 37 and 45 degrees C. The rate of this reaction was measured in several aqueous buffers with different pH values, showing minimal formation of pyroglutamic acid at pH 6.2 and increased formation of pyroglutamic acid at pH 4 and pH 8. The half-life of the N-terminal glutamic acid was approximately 9 months in a pH 4.1 buffer at 45 degrees C. To our knowledge, we showed for the first time that glutamic acid residues located at the N-terminus of proteins undergo pyroglutamic acid formation in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16579622     DOI: 10.1021/ac051827k

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  38 in total

1.  Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media.

Authors:  Timothy Kaschak; Daniel Boyd; Franklin Lu; Gayle Derfus; Brian Kluck; Bartek Nogal; Craig Emery; Christie Summers; Kai Zheng; Robert Bayer; Ashraf Amanullah; Boxu Yan
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies.

Authors:  Y Diana Liu; Andrew M Goetze; Randal B Bass; Gregory C Flynn
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

3.  Molecular mass analysis of antibodies by on-line SEC-MS.

Authors:  Lowell J Brady; John Valliere-Douglass; Theresa Martinez; Alain Balland
Journal:  J Am Soc Mass Spectrom       Date:  2008-01-04       Impact factor: 3.109

4.  Determination of primary structure and microheterogeneity of a beta-amyloid plaque-specific antibody using high-performance LC-tandem mass spectrometry.

Authors:  Irina Perdivara; Leesa Deterding; Adrian Moise; Kenneth B Tomer; Michael Przybylski
Journal:  Anal Bioanal Chem       Date:  2008-03-28       Impact factor: 4.142

5.  Analysis of reduced monoclonal antibodies using size exclusion chromatography coupled with mass spectrometry.

Authors:  Hongcheng Liu; Georgeen Gaza-Bulseco; Chris Chumsae
Journal:  J Am Soc Mass Spectrom       Date:  2009-08-28       Impact factor: 3.109

Review 6.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

Review 7.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

8.  Antibody characterization using novel ERLIC-MS/MS-based peptide mapping.

Authors:  Jing Zhen; John Kim; Ying Zhou; Ervinas Gaidamauskas; Shyamsundar Subramanian; Ping Feng
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857

9.  Mass spectrometric distinction of in-source and in-solution pyroglutamate and succinimide in proteins: a case study on rhG-CSF.

Authors:  Mukesh Kumar; Amarnath Chatterjee; Anand P Khedkar; Mutyalasetty Kusumanchi; Laxmi Adhikary
Journal:  J Am Soc Mass Spectrom       Date:  2013-01-03       Impact factor: 3.109

10.  Rational Design of Potent Activators and Inhibitors of the Enterococcus faecalis Fsr Quorum Sensing Circuit.

Authors:  Dominic N McBrayer; Crissey D Cameron; Brooke K Gantman; Yftah Tal-Gan
Journal:  ACS Chem Biol       Date:  2018-09-07       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.